Inhibrx Biosciences Inc.
INBX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.06B
Close$
$0.81
98.9% downside
Current Fair Value
98.9% downsideOvervalued by 98.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.06 Billion |
|---|---|
| Enterprise Value | $928.43 Million |
| Earnings per Share | $-9.04 |
| Beta | 3.82 |
| Outstanding Shares | 15,669,000 |
Return
| Return on Equity | 260.83% |
|---|---|
| Return on Assets | -89.60% |
| Return on Invested Capital | -100.40% |
Valuation & Multiples
| P/E Ratio | -8.08 |
|---|---|
| PEG | -28.97 |
| Price to Sales | - |
| Price to Book Ratio | -18.04 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.33 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.1 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-1.90
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-2.45
Consensus analyst estimateRevenue Estimate
$1.90 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 14.70% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.47%▼ 91.18% |
|---|---|
| Total Invested | $7.47M▼ 99.45% |
| Investors Holding | 28▼ 150.00% |
About Inhibrx Inc
88 employees
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the spe...